New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.
Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.
Expert highlights how taste-masking, dose, and particle size influence patient adherence and the clinical performance of fast-dissolving delivery systems.
Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.
Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.
Discover the benefits of fast melt tablets, designed for easy swallowing and quick disintegration, enhancing patient convenience and adherence.
An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.
An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.
An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.
A panelist discusses how pharmacists can overcome patient reluctance to shingles vaccination by transparently addressing adverse effect concerns, using multiple patient interactions to build acceptance over time, and sharing personal stories about shingles complications to help patients understand the real risks of the disease.
Learn how pharmacists can improve shingles vaccine completion rates by using physician orders rather than verbal recommendations, addressing individual patient concerns about vaccine fatigue and hesitancy, and proactively scheduling second doses during the first visit to ensure full protection.
Crystal Hodge, PharmD, BCIDP, BCPS, discusses a 3-pronged approach—isolating, vaccinating, and educating—to help pharmacists manage respiratory virus season and routine immunizations like MMR.
Pharmacists play a crucial role in managing myelofibrosis, enhancing patient education, adherence, and financial navigation for optimal care.
Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.
Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).
Crystal Hodge, PharmD, BCIDP, BCPS, emphasizes that declining vaccination rates below the 95% herd immunity threshold have fueled recent measles outbreaks, underscoring the urgent need for pharmacist-led vaccination advocacy.
Legislative efforts aim to improve oncology medication access, addressing transportation barriers and advocating for mail delivery from cancer clinics.
E. Camille Vaughan, MD, MS, highlights how pharmacists can build patient trust, encourage vaccination, and use simple strategies to spark conversations with hesitant individuals.
An expert emphasizes the importance of prompt antiviral treatment and personalized pain management for shingles—particularly in high-risk patients—while highlighting the pharmacist’s role in guiding appropriate over-the-counter care, promoting vaccination through timely conversations, and leveraging tools like immunization registries and word of mouth to improve prevention efforts.
Trisha Winroth, PharmD, highlights the critical role of vaccination in preventing shingles—especially for high-risk patients with chronic conditions—while addressing challenges such as postpandemic vaccine fatigue. She emphasizes pharmacists’ unique position to build trust, offer timely education during routine visits, and improve uptake through personalized, visually supported, and seasonally timed conversations.
Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).
Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).
E. Camille Vaughan, MD, MS, addresses how state-level differences and potential new prescription requirements could impact patient access to COVID-19 vaccines this fall.
Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.
Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.
E. Camille Vaughan, MD, MS, highlights the key role pharmacists play in providing clear, trusted guidance for patients seeking COVID-19 vaccines this fall.
A chief pharmacy officer emphasizes the vital role of pharmacists in enhancing patient care, advocating for recognition, and integration within health care systems.
Allison Hill, PharmD, RPh, highlights the need for pharmacists to leverage resources, collaborate with other providers, advocate on social media, and support rural communities with limited access to care.
A panelist discusses how emerging chronic myeloid leukemia treatment advancements, including the addition of asciminib as a frontline tyrosine kinase inhibitor (TKI) option and ongoing research into dual TKI therapy and optimal dosing strategies, are expanding therapeutic choices while pharmacists play a key role in educating patients and providers about evolving treatment algorithms, evaluating new literature, and helping teams manage newer agents with less clinical experience.
